Mainz Biomed (NASDAQ:MYNZ) Lowered to Hold Rating by Maxim Group

Maxim Group cut shares of Mainz Biomed (NASDAQ:MYNZ) from a strong-buy rating to a hold rating in a research report sent to investors on Friday,Zacks.com reports.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. Wall Street Zen upgraded Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce”.

Mainz Biomed Price Performance

Shares of MYNZ stock traded up $0.02 during midday trading on Friday, reaching $0.83. 180,667 shares of the company traded hands, compared to its average volume of 612,304. The firm’s 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $1.28. The firm has a market cap of $7.52 million, a PE ratio of -0.01 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.52 and a quick ratio of 0.43. Mainz Biomed has a 1-year low of $0.55 and a 1-year high of $5.62.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Armistice Capital LLC raised its position in shares of Mainz Biomed by 96.5% during the 4th quarter. Armistice Capital LLC now owns 775,263 shares of the company’s stock worth $868,000 after purchasing an additional 380,744 shares during the last quarter. Cerity Partners LLC acquired a new stake in Mainz Biomed during the 4th quarter valued at $183,000. Finally, Steward Partners Investment Advisory LLC increased its position in Mainz Biomed by 200.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.